Medical Policy
Preimplantation Genetic Testing

Document Number: 004

<table>
<thead>
<tr>
<th></th>
<th>Commercial* and Connector/ Qualified Health Plans</th>
<th>MassHealth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorization required</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>No notification or authorization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not covered</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

* Not all commercial plans cover this service, please check plan’s benefit package to verify coverage.

Overview
The purpose of this document is to describe the guidelines AllWays Health Partners utilizes to determine medical appropriateness for preimplantation genetic testing (PGT) which includes preimplantation genetic diagnosis (PGD) for single gene defects and translocations, and preimplantation genetic screening (PGS) for aneuploidy.

Coverage Guidelines
AllWays Health Partners covers medically necessary PGD (and associated assisted reproductive services; e.g. IVF, ICSI) for a debilitating, genetically-defined and genetically predictable disease with early onset mortality or morbidity when there is no known treatment for the condition or the available interventions are either inadequately effective or significantly burdensome. AllWays Health Partners does not cover PGS.

The specialist and/or the primary care provider are responsible for providing all necessary clinical information including medical history of patient and partner or child, where appropriate. It is expected that the member/couple are counselled regarding the testing alternatives to PGD (e.g. amniocentesis, chorionic villous sampling), potential risks of PGD (embryo arrest, diagnostic uncertainly and unknown long-term effects of PGD), and that traditional prenatal diagnostic testing may still be recommended after successful PGD and pregnancy.

Authorization of PGD is limited to the following criteria:

Preimplantation Genetic Diagnosis (PGD)
1. AllWays Health Partners covers medically necessary PGD to test for unbalanced chromosome rearrangements when one of the genetic parents is known to have a balanced reciprocal translocation or Robertsonian translocation, or to have a microdeletion /duplication with one previously affected child. AllWays Health Partners may require laboratory documentation of the genetic tests.
2. AllWays Health Partners covers medically necessary PGD to detect evidence of any of the following genetic disorders in an embryo when:
a. Both genetic parents are known carriers of a single gene autosomal recessive disorder, or one of the genetic parents is a known carrier and they have a child who has been diagnosed with the disorder such as, but not limited to the following:
   i. Canavan disease
   ii. Cystic Fibrosis
   iii. Epidermolysis Bullosa Simplex (autosomal recessive type)
   iv. Familial dysautonomia
   v. Fanconi’s Anemia
   vi. Gaucher Disease
   vii. Hurler Syndrome
   viii. Methylmalonic acidemia
   ix. Propionic academia
   x. Sickle Cell Anemia
   xi. Spinal Muscular Atrophy Type I
   xii. Spinocerebellar Ataxia (autosomal recessive type)
   xiii. Tay-Sachs Disease
   xiv. Thalassemia Syndromes

b. One genetic parent is a known carrier of a single gene autosomal dominant disorder such as, but not limited to, the following:
   i. Epidermolysis Bullosa (autosomal dominant type)
   ii. Huntington’s Disease
   iii. Myotonic Dystrophy
   iv. Neurofibromatosis Type II
   v. Spinocerebellar Ataxia (autosomal dominant type)
   vi. Tuberous sclerosis

c. The genetic female parent is a known carrier of a single gene X-linked recessive disorder such as, but not limited to the following:
   i. Adrenoleukodystrophy
   ii. Alport Syndrome
   iii. Becker muscular dystrophy
   iv. Fabry disease
   v. Choroideremia
   vi. Duchenne muscular dystrophy
   vii. Fragile X syndrome
   viii. Hemophilia A & B
   ix. Hunter Syndrome
   x. Incontinentia pigmenti
   xi. Lesch-Nyhan Syndrome
   xii. X-linked intellectual disability
Exclusions

1. PGD services for any reason other than listed above.
2. PGT as an adjunct to infertility services for members who are not eligible for such services as determined by the Preimplantation Genetic Testing clinical coverage criteria.
3. PGD Services if the member or member’s spouse are using illicit substances or abusing substances known to negatively interfere with fertility or fetal development (e.g., marijuana, opiates, cocaine, or alcohol);
4. PGT for:
   a. Screening for aneuploidy including in the setting of: recurrent miscarriage, repeated failed implantation during IVF, or advanced maternal age.
   b. Screening for genetic or chromosomal abnormalities or traits in the absence of a known, clinically significant genetic or chromosomal condition in the genetic parents.
   c. Carrier testing to determine embryo’s carrier status.
   d. Human Leukocyte antigen (HLA) typing of an embryo to identify a future suitable stem cell, tissue or organ transplantation donor.
   e. Translocations which will always produce an abnormal gamete such as 45XX (21;21) & 45XY(21;21)
   f. Gender selection in the absence of a documented X-linked disorder.
   g. Selecting non-medical traits.
   h. Selecting against predisposition to disease when there is no single known genetic or chromosomal defect that definitively causes the disease.
   i. Late onset/adult onset disorders that are not listed in criteria above.
   j. Genetic conditions contributed to by donor egg and sperm.

Definitions

Autosomal Dominant: Autosomal dominant is one of several ways that a trait or disorder can be passed down through families. If a disease is autosomal dominant, it means you only need to get the abnormal gene from one parent in order for you to inherit the disease. One of the parents may often have the disease.

Autosomal Recessive: A disorder characterized by two mutated copies of the gene must be present in each cell in order for the disease or trait to develop. Affected persons usually have two unaffected parents who each carry a single copy of the mutated gene and they are known as carriers.

Preimplantation Genetic Diagnosis: A test involving an embryo that has been created using assisted reproductive technology such as in-vitro fertilization. After the eggs are removed the eggs are fertilized. Those eggs which are successfully fertilized are developed into a blastomere or a blastocyst. One or two cells are removed in order to test for the specific genetic condition in question.

X-linked Dominant Disorders: Caused by mutations in the gene on the X chromosome. Females are more frequently affected than males and the chances of passing on an X linked dominant disorder differ between men and women.
X-Linked Recessive: Are caused by mutations in the genes on the X chromosome. Males are more frequently affected than females and the chances of passing on the disorder differ between men and women. Families with an X linked recessive disorder often have affected males but rarely affected females in each generation. A characteristic of X linked inheritance is that fathers cannot pass X-linked traits to their sons.

**CPT/HCPC Codes**

<table>
<thead>
<tr>
<th>Authorized CPT/HCPCS Codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>89290</td>
<td>Biopsy, oocyte polar body or embryo blastomere, micro technique (for pre-implantation genetic diagnosis); less than or equal to 5 embryos</td>
</tr>
<tr>
<td>89291</td>
<td>Biopsy, oocyte polar body or embryo blastomere, micro technique (for pre-implantation genetic diagnosis); greater than 5 embryos</td>
</tr>
</tbody>
</table>

**Related Policies**

- [Assisted Reproductive Services/Infertility Services](#)

**Effective**

- March 2019: Annual update. Updated references.
- August 2018: Added language under item 1 subheading Preimplantation Genetic Diagnosis to include *(and associated assisted reproductive services; e.g. IVF, ICSI).*
- April 2018: Annual update.
- July 2017: Annual update. Added the exclusion “PGD Services if the member or member’s spouse are using illicit substances or abusing substances known to negatively interfere with fertility or fetal development (e.g., marijuana, opiates, cocaine, or alcohol)”
- July 2016: Annual update
- July 2015: Updated references
- August 2014: Added language to Coverage Guidelines, “a debilitating genetic disease with early onset mortality or morbidity and when there is no known treatment for the condition or the available interventions are either inadequately effective or significantly burdensome.” Added exclusions: 3f selecting for non-medical traits and 3j Genetic conditions contributed to by donor egg and sperm.
- June 2013: Annual update, added specific genetic disorders.
- June 2012: Effective date.

**References**

- Brezina PR, and Kutteh WH, Clinical Applications of Preimplantation Genetic Testing. *BMJ* 2014;349:g761.doi: 10.1136/bmj.g7611


